Literature DB >> 16132115

Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV).

Szu-Chia Lai1, Pele Choi-Sing Chong, Chia-Tsui Yeh, Levent Shih-Jen Liu, Jia-Tsrong Jan, Hsiang-Yun Chi, Hwan-Wun Liu, Ann Chen, Yeau-Ching Wang.   

Abstract

The spike (S) glycoprotein is thought to play a complex and central role in the biology and pathogenesis of SARS coronavirus infection. In this study, a recombinant protein (rS268, corresponding to residues 268-1255 of SARS-CoV S protein) was expressed in Escherichia coli and was purified to near homogeneity. After immunization with rS268, S protein-specific BALB/c antisera and mAbs were induced and confirmed using ELISA, Western blot and IFA. Several BALB/c mAbs were found to be effectively to neutralize the infection of Vero E6 cells by SARS-CoV in a dose-dependent manner. Systematic epitope mapping showed that all these neutralizing mAbs recognized a 15-residues peptide (CB-119) corresponding to residues 1143-1157 (SPDVDLGDISGINAS) that was located to the second heptad repeat (HR2) region of the SARS-CoV spike protein. The peptide CB-119 could specifically inhibit the interaction of neutralizing mAbs and spike protein in a dose-dependent manner. Further, neutralizing mAbs, but not control mAbs, could specifically interact with CB-119 in a dose-dependent manner. Results implicated that the second heptad repeat region of spike protein could be a good target for vaccine development against SARS-CoV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132115      PMCID: PMC7089214          DOI: 10.1007/s11373-005-9004-3

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  32 in total

1.  Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays.

Authors:  D D LaBarre; R J Lowy
Journal:  J Virol Methods       Date:  2001-08       Impact factor: 2.014

2.  Peptides derived from the heptad repeat region near the C-terminal of Sendai virus F protein bind the hemagglutinin-neuraminidase ectodomain.

Authors:  Maurizio Tomasi; Claudia Pasti; Cristina Manfrinato; Franco Dallocchio; Tiziana Bellini
Journal:  FEBS Lett       Date:  2003-02-11       Impact factor: 4.124

3.  Continuous cultures of fused cells secreting antibody of predefined specificity. 1975.

Authors:  G Köhler; C Milstein
Journal:  Biotechnology       Date:  1992

4.  Neutralization-resistant variants of a neurotropic coronavirus are generated by deletions within the amino-terminal half of the spike glycoprotein.

Authors:  T M Gallagher; S E Parker; M J Buchmeier
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

5.  Identification of an immunodominant linear neutralization domain on the S2 portion of the murine coronavirus spike glycoprotein and evidence that it forms part of complex tridimensional structure.

Authors:  C Daniel; R Anderson; M J Buchmeier; J O Fleming; W J Spaan; H Wege; P J Talbot
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

6.  The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex.

Authors:  Berend Jan Bosch; Ruurd van der Zee; Cornelis A M de Haan; Peter J M Rottier
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

7.  The V5A13.1 envelope glycoprotein deletion mutant of mouse hepatitis virus type-4 is neuroattenuated by its reduced rate of spread in the central nervous system.

Authors:  J K Fazakerley; S E Parker; F Bloom; M J Buchmeier
Journal:  Virology       Date:  1992-03       Impact factor: 3.616

8.  C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.

Authors:  R J Medinas; D M Lambert; W A Tompkins
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  A clustering of RNA recombination sites adjacent to a hypervariable region of the peplomer gene of murine coronavirus.

Authors:  L R Banner; J G Keck; M M Lai
Journal:  Virology       Date:  1990-04       Impact factor: 3.616

10.  A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses.

Authors:  D Rapaport; M Ovadia; Y Shai
Journal:  EMBO J       Date:  1995-11-15       Impact factor: 11.598

View more
  30 in total

1.  Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.

Authors:  Jianhua Sui; Meagan Deming; Barry Rockx; Robert C Liddington; Quan Karen Zhu; Ralph S Baric; Wayne A Marasco
Journal:  J Virol       Date:  2014-09-17       Impact factor: 5.103

2.  SARS coronavirus vaccine development.

Authors:  Ralph S Baric; Timothy Sheahan; Damon Deming; Eric Donaldson; Boyd Yount; Amy C Sims; Rhonda S Roberts; Matthew Frieman; Barry Rockx
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

3.  Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus.

Authors:  Barry Rockx; Eric Donaldson; Matthew Frieman; Timothy Sheahan; Davide Corti; Antonio Lanzavecchia; Ralph S Baric
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

4.  Identification and characterization of dominant helper T-cell epitopes in the nucleocapsid protein of severe acute respiratory syndrome coronavirus.

Authors:  Jincun Zhao; Qianrong Huang; Wei Wang; Yan Zhang; Ping Lv; Xiao-Ming Gao
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

5.  Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).

Authors:  Mavanur R Suresh; Pravin K Bhatnagar; Dipankar Das
Journal:  J Pharm Pharm Sci       Date:  2008-04-19       Impact factor: 2.327

6.  Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.

Authors:  Barry Rockx; Davide Corti; Eric Donaldson; Timothy Sheahan; Konrad Stadler; Antonio Lanzavecchia; Ralph Baric
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

7.  Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.

Authors:  Jie Li; Laura Ulitzky; Erica Silberstein; Deborah R Taylor; Raphael Viscidi
Journal:  Viral Immunol       Date:  2013-04       Impact factor: 2.257

Review 8.  The spike protein of SARS-CoV--a target for vaccine and therapeutic development.

Authors:  Lanying Du; Yuxian He; Yusen Zhou; Shuwen Liu; Bo-Jian Zheng; Shibo Jiang
Journal:  Nat Rev Microbiol       Date:  2009-02-09       Impact factor: 60.633

9.  Landscape and selection of vaccine epitopes in SARS-CoV-2.

Authors:  Christof C Smith; Kelly S Olsen; Benjamin G Vincent; Alex Rubinsteyn; Kaylee M Gentry; Maria Sambade; Wolfgang Beck; Jason Garness; Sarah Entwistle; Caryn Willis; Steven Vensko; Allison Woods; Misha Fini; Brandon Carpenter; Eric Routh; Julia Kodysh; Timothy O'Donnell; Carsten Haber; Kirsten Heiss; Volker Stadler; Erik Garrison; Adam M Sandor; Jenny P Y Ting; Jared Weiss; Krzysztof Krajewski; Oliver C Grant; Robert J Woods; Mark Heise
Journal:  Genome Med       Date:  2021-06-14       Impact factor: 15.266

10.  Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing.

Authors:  Hatem A Elshabrawy; Melissa M Coughlin; Susan C Baker; Bellur S Prabhakar
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.